BIOCARDIA INC

BioCardia insider buying surge shows CEO confidence; investors eye pipeline, partnership news, and volatility for upside potential.

Altman’s recent bulk buy of BIOCARDIA shares signals confidence in its CardAMP program and FDA‑backed trials, hinting at future upside.

BioCardia CEO’s steady insider buying shows confidence amid a 60% share drop—investors should watch clinical milestones for upside.

CEO Altman’s latest BioCardia buy signals confidence amid price volatility—discover how insider action could impact your investment strategy.

BioCardia insider buying: CEO Peter Altman’s fresh purchase signals renewed confidence in the company’s cardiovascular pipeline and may drive future upside for investors.

CEO insider buying at BIOCARDIA: Peter Altman’s 5,000‑share purchase amid a 22% slide signals confidence, potential rebound if regulatory milestones hit.

CEO’s latest BioCardia share purchase signals confidence amid 54% stock decline—could spark a rebound before the upcoming earnings report.

CEO’s recent insider buys signal confidence in BioCardia’s upcoming FDA talks, new Japanese patent, and potential upside for investors.

CEO Altman Peter’s steady, near‑market purchases of BioCardia shares signal strong internal confidence and a bullish cue for long‑term investors amid promising clinical progress.

BioCardia’s CEO’s steady insider buying signals confidence in a turnaround—learn how his 70% share increase could affect the stock’s future.